SEC Form 5 · accession 0000899243-17-003462
Corvus Pharmaceuticals, Inc. · CRVS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Leiv Lea
Officer — Chief Financial Officer
Period of report
Dec 31, 2016
Accepted (ET)
Feb 10, 2017 · 4:18 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001626971
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock, $0.0001 par valueF1,F2 | Aug 25, 2016 | G | 48,000 | $0.00 | D | 151,253 | I | By Trust |
| Common Stock, $0.0001 par valueF1,F2 | Aug 25, 2016 | G | 2,047 | $0.00 | D | 149,206 | I | By Trust |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1A portion of these shares is subject to a right of repurchase held by the Issuer.
- F2These shares are held by Leiv Lea and Deborah Karlson, Trustees of the Karlson Lea Family Trust UTA dated February 11, 1998 (the "Karlson Lea Trust"). Mr. Lea has shared voting, investment and dispositive power over the shares held by the Karlson Lea Trust.